<DOC>
<DOCNO>EP-0621901</DOCNO> 
<TEXT>
<INVENTION-TITLE>
PROCESS FOR SCREENING SUBSTANCES CAPABLE OF MODULATING A RECEPTOR-DEPENDENT CELLULAR SIGNAL TRANSDUCTION PATHWAY
</INVENTION-TITLE>
<CLASSIFICATIONS>C12Q144	C12N510	C12N500	C12Q166	C12N510	G01N3350	C07K14705	C12N1512	C12R191	C12Q168	C12Q168	G01N3350	C12N500	C12Q144	C12N1509	C07K14435	C12N1553	C12N1509	C12Q166	C12N1512	C12N1553	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C12Q	C12N	C12N	C12Q	C12N	G01N	C07K	C12N	C12R	C12Q	C12Q	G01N	C12N	C12Q	C12N	C07K	C12N	C12N	C12Q	C12N	C12N	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C12Q1	C12N5	C12N5	C12Q1	C12N5	G01N33	C07K14	C12N15	C12R1	C12Q1	C12Q1	G01N33	C12N5	C12Q1	C12N15	C07K14	C12N15	C12N15	C12Q1	C12N15	C12N15	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
BOEHRINGER INGELHEIM INT
</APPLICANT-NAME>
<APPLICANT-NAME>
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
CZERNILOFSKY ARMIN PETER
</INVENTOR-NAME>
<INVENTOR-NAME>
HIMMLER ADOLF
</INVENTOR-NAME>
<INVENTOR-NAME>
LAMCHE HERBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHAEFER RENATE
</INVENTOR-NAME>
<INVENTOR-NAME>
STRATOWA CHRISTIAN
</INVENTOR-NAME>
<INVENTOR-NAME>
WEYER ULRIKE
</INVENTOR-NAME>
<INVENTOR-NAME>
CZERNILOFSKY, ARMIN, PETER
</INVENTOR-NAME>
<INVENTOR-NAME>
HIMMLER, ADOLF
</INVENTOR-NAME>
<INVENTOR-NAME>
LAMCHE, HERBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHAEFER, RENATE
</INVENTOR-NAME>
<INVENTOR-NAME>
STRATOWA, CHRISTIAN
</INVENTOR-NAME>
<INVENTOR-NAME>
WEYER, ULRIKE
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Process for determining the modulating effect of a
substance on a receptor-dependent signal transduction

pathway in a human or animal cell, characterised in that
the modulating effect of the substance on the activity

of a phospholipase or on a mechanism which precedes or
succeeds the phospholipase activation in the signal

transduction pathway initiated by a receptor coupled to
the signal transduction pathway, is determined by

incubating mammalian cells which

a) are transformed with a recombinant DNA
containing a reporter gene and a regulatory

sequence which responds to the change in
concentration of inositol-1,4,5-triphosphate (IP
3
)
and a diacylglycerol (DAG) brought about by the

modulation of the phospholipase activity, so that
the expression of the reporter gene is modulated by

a change in concentration of IP
3
/DAG, and which are
furthermore
b) transformed with a recombinant DNA, containing a
sequence which codes for a receptor which is

coupled to the phospholipase effector system so
that the cells express the receptor,

with the test substance and measuring the concentration
of the reporter gene product.
Process according to claim 1, characterised in that
the recombinant DNA defined in b) contains a sequence

which codes for a human receptor.
Process according to claim 1 or 2, characterised in
that the recombinant DNA defined in a) contains a

regulatory sequence which responds to the change in
concentration of IP
3
 and DAG brought about by modulation
of phospholipase C, and that the recombinant DNA defined 

in b) contains a sequence which codes for a G-protein
coupled receptor.
Process according to one of claims 1 to 3,
characterised in that, furthermore, mammalian cells

which are transformed only with the recombinant DNA
defined in a) are incubated with the test substance

under identical conditions and the concentration of the
reporter gene product is measured.
Process according to one of claims 1 to 4,
characterised in that, moreover, mammalian cells which

are transformed with recombinant DNA containing the
reporter gene and a regulatory sequence which responds

to the change in concentration of cAMP brought about by
the modulation of adenylate cyclase so that the

expression of the reporter gene is modulated by the
change in concentration of cAMP are incubated with the

test substance and the concentration of the reporter
gene product is measured.
Process according to claim 5, characterised in
that, moreover, cells which are transformed with the

recombinant DNA responding to cAMP and with a
recombinant DNA defined in b), containing the sequence

coding for the same receptor as the cells which are
transformed with recombinant DNA responding to IP
3
/DAG,
are incubated with the test substance and the

concentration of the reporter gene product is measured.
Process according to claim 5, characterised in
that, moreover, cells which are transformed with a

recombinant DNA, containing a sequence coding for a
receptor which is coupled to the adenylate cyclase

effector system in such a way that the cells express the
receptor, are incubated with the test substance and the

concentration of the reporter gene product is measured. 
Process according to one of claims 1 to 7,
characterised in that it is used as a screening assay in

which the test substance is one of a number of
substances with which a predetermined number of

mammalian cells are incubated under predetermined
conditions and the concentration of the reporter gene

product is measured.
Process according to claim 8, characterised in
that, as the reporter gene product, luciferase is

measured in the presence of a reagent which contains a
detergent suitable for lysing the cells, a buffer having

a pH from 6 to 9, preferably pH 7 to 8, a magnesium

salt, preferably magnesium sulphate, adenosine
triphosphate, luciferin, a mild organic reducing agent

such as dithiothreitol and/or Î²-mercaptoethanol and
optionally sodium tripolyphosphate and/or sodium

pyrophosphate.
Recombinant DNA containing a reporter gene and an
expression control sequence functionally connected

therewith for the expression in mammalian cells,
characterised in that the expression control sequence

contains a regulatory sequence which responds to the
change in concentration of IP
3
 and DAG brought about by
the modulation of phospholipase, for use in a process

according to one of the preceding claims.
Recombinant DNA according to claim 10,
characterised in that it contains a regulatory sequence

of natural origin.
Recombinant DNA according to claim 11,
characterised in that it contains the 5'-regulatory

sequence of a gene which can be induced by IP
3
/DAG. 
Recombinant DNA according to claim 12,
characterised in that it contains the 5'-regulatory

sequence of the ICAM-1 gene.
Recombinant DNA according to claim 10,
characterised in that the regulatory sequence is

synthetically produced.
Recombinant DNA according to claim 14,
characterised in that the regulatory sequence contains a

plurality of regulatory elements responding to the
modulation of IP
3
/DAG spaced from one another.
Recombinant DNA according to claim 15,
characterised in that it contains three to twelve

regulatory elements.
Recombinant DNA according to claim 15 or 16,
characterised in that at least some of the regulatory

elements and/or the sequence sections located between
them differ from one another.
Recombinant DNA according to claim 16 or 17,
characterised in that it contains three TRE-elements of

the ICAM-1 gene.
Recombinant DNA according to claim 16 or 17,
characterised in that it contains six TRE-elements of

the ICAM-1 gene.
Recombinant DNA according to one of claims 10 to
19, characterised in that it contains a luciferase gene

as reporter gene.
Recombinant DNA according to one of claims 10 to
20, characterised in that it contains a marker gene. 
Mammalian cells transformed with a recombinant DNA
according to one of claims 10 to 21.
Mammalian cells according to claim 22,
characterised in that they are moreover transformed with

a recombinant DNA containing a sequence coding for a
receptor which is coupled to the phospholipase effector

system in such a way that the cells express the
receptor.
Mammalian cells according to claim 23,
characterised in that the recombinant DNA contains a

sequence coding for a human receptor.
Mammalian cells according to claim 23 or 24,
characterised in that the recombinant DNA contains a

sequence coding for a G-protein-coupled receptor.
Mammalian cells according to claim 25,
characterised in that the expression control sequence

contains a regulatory sequence which responds to the
change in concentration of IP
3
 and DAG caused by the
modulation of phospholipase C.
Mammalian cells according to claim 26,
characterised in that they are transformed with

recombinant DNA containing a sequence coding for a
receptor, selected from the group comprising serotonin

receptors of the 5-HT
1C
- and 5-HT
2
-type, thrombin
receptor, neuropeptide Y-receptors, neurokinin

receptors, PAF-receptors, angiotensin receptors,
muscarinic acetylcholine receptors of the M
1
-, M
3
- and
M
5
-type.
Recombinant DNA, containing a reporter gene and an
expression control sequence functionally connected

therewith for expression in mammalian cells, wherein the 
expression control sequence contains a synthetically

produced regulatory sequence which responds to the
change in concentration of cAMP brought about by

modulation of adenylate cyclase, characterised in that
the regulatory sequence contains a plurality of

regulatory elements responding to the modulation of
cAMP, spaced apart from one another, for use in a

process according to one of claims 5 to 9.
Recombinant DNA according to claim 28,
characterised in that it contains three to twelve

regulatory elements.
Recombinant DNA according to claim 28 or 29,
characterised in that at least some of the regulatory

elements and/or the sequence sections located between
them differ from one another.
Recombinant DNA according to one of claims 28 to
30, characterised in that it contains a luciferase gene

as the reporter gene.
Recombinant DNA according to one of claims 28 to
31, characterised in that it contains a marker gene.
Mammalian cells transformed with a recombinant DNA
according to one of claims 28 to 32.
Mammalian cells according to claim 33,
characterised in that they are furthermore transformed

with a recombinant DNA containing a sequence coding for
a receptor which is coupled to the phospholipase

effector system, so that the cells express the receptor. 
Mammalian cells according to claim 34, characterised
in that they are transformed with recombinant DNA

containing a sequence coding for a receptor selected from
the group comprising serotonin receptors of the 5-HT
1C
-
and 5-HT
2
-type, thrombin receptor, neuropeptide Y-receptors,
neurokinin receptors, PAF-receptors,

angiotensin receptors and muscarinic acetylcholine
receptors of the M
1
-, M
3
- and M
5
-type.
Mammalian cells according to claim 33, characterised
in that they are also transformed with a recombinant DNA

containing a sequence coding for a receptor which is
coupled to the adenylate cyclase effector system, in such

a way that the cells express the receptor.
Mammalian cells according to claim 36, characterised
in that they are transformed with recombinant DNA

containing a sequence coding for a receptor, selected from
the group comprising muscarinic acetylcholine receptors of

the M
2
- and M
4
-type, dopamine receptors of the D
1
-, D
21
-,
D
2s
- and D
5
-type, serotonin receptors of the 5-HT
1A
- and 5-HT
1D
-type
and adenosine receptors of the A
1
- and A
2
-type.
</CLAIMS>
</TEXT>
</DOC>
